Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency-Coblation (Nucleoplasty)
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage for laser discectomy and disc nucleoplasty (radiofrequency coblation) for patients with discogenic low back pain or radiculopathy for members of Blue Cross and Blue Shield of Kansas.
No material clinical or coverage changes in this revision.
Coverage Determination and Evidence
Coverage determination
Covered when ALL of the following are met
Refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage.
Laser discectomy — evidence limitations
Evidence summary for laser discectomy
Observational studies are insufficient to permit conclusions concerning effects on health outcomes due to variable natural history and potential placebo effects.
Comparative retrospective reviews lacked statistical comparisons; case series subject to selection and reporting bias.
Disc nucleoplasty — evidence and limitations
Evidence summary for disc nucleoplasty (radiofrequency coblation)
Secondary procedure rates and long-term outcomes varied across trials; interpret results cautiously due to methodological limitations.
Trials provide some evidence of short-term benefit but are limited for drawing definitive conclusions about long-term effectiveness and comparative effectiveness versus standard surgical approaches.
Procedures discussed in this policy — specifically laser discectomy and radiofrequency coblation (disc nucleoplasty) — are designated experimental/investigational and are not covered under this medical policy. Coverage for these services for an individual member is determined by the member's contract benefits in effect at the time of service; providers should verify benefits with Blue Cross and Blue Shield of Kansas prior to scheduling or billing.
The available evidence for laser discectomy is primarily from observational studies and case series. Because of the variable natural history of back pain and the potential for placebo effects, these observational data are insufficient to permit conclusions about the procedure's effects on health outcomes.
Earlier iterations of this policy explicitly stated that both laser discectomy and radiofrequency coblation (disc nucleoplasty) were considered experimental/investigational. The policy text has been updated over time, but the historical policy record (including revisions and rationale) reflects that these techniques have long been treated as investigational.
Given the limited observational evidence base for decompression using laser energy and the documented possibility of placebo effects in this area, the literature does not demonstrate sufficient evidence that percutaneous decompression with laser energy improves health outcomes; therefore the procedure lacks adequate evidence to support coverage as medically necessary.
The inclusion or exclusion of procedure, diagnosis, or device codes in the coding section is provided for informational purposes only and does not, by itself, constitute or imply member coverage. Determinations of medical necessity and coverage depend on whether the procedure is performed in accordance with the policy criteria and on the member's contract benefits in effect at the time of service.
Coding and Regulatory Identifiers
| GEX | FDA product code for laser devices (percutaneous discectomy indications) |
| GEI | FDA product code for Perc-D SpineWand / coblation devices |
| 62287 | Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar. |
| 77002 | Fluoroscopic guidance for needle placement (e.g., biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure). |
| S2348 | Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar |
What Providers Must Do
Verify member benefits
Coverage is determined by the member's contract benefits in effect at the time of service. Verify eligibility and benefit coverage with Blue Cross and Blue Shield of Kansas Customer Service prior to scheduling or performing procedures.
- Refer to member contract for coverage determination
- Contact BCBSKS Customer Service to verify eligibility and benefits
Prior authorization — contact payer
Prior authorization may be required. Providers should contact Blue Cross and Blue Shield of Kansas (BCBSKS) for prior authorization requirements and any questions about coverage before performing the procedure.
- Contact BCBSKS Customer Service or professional/institutional relations for prior authorization and coverage inquiries
Procedure coding and requirement
The procedure codes listed are informational only. Inclusion or exclusion of codes does not guarantee coverage. Codes are medically necessary ONLY when the procedure is performed in accordance with the Policy section of this document.
Experimental / Investigational designation
Laser discectomy and radiofrequency coblation (disc nucleoplasty) are considered experimental/investigational for disc decompression and treatment of associated pain. Coverage for these procedures should be determined per the member's contract.
- Designated experimental/investigational — coverage determined by member contract benefits
FDA device indication notes
FDA-cleared device summaries note indications that generally include symptoms and imaging consistent with a target disc and failure to respond to a period of conservative therapy (e.g., symptoms unresponsive to 12 weeks of conservative treatment). Device clearances are for specific laser systems and list intended uses related to percutaneous discectomy/decompression.
- FDA summaries reference 12 weeks of failed conservative therapy as part of device indications
- Trimedyne and other laser systems cleared via 510(k) for percutaneous disc procedures (product code GEX)
Supporting trial documentation and prior therapy
Clinical trials and supporting documentation commonly required or referenced in the literature included prior conservative therapies and described baseline characteristics and prior treatments. Trials reported whether patients had failed or previously received epidural steroid injections or other conservative management before enrollment.
- Gerszten RCT: all patients had previously had an epidural steroid injection within 3 weeks to 6 months with variable relief
- Chitragran RCT and other trials reported prior conservative care in enrolled populations
Conservative therapy precedes invasive options
Conservative management (physical therapy, medication management) and epidural steroid injections are typical initial therapies and should precede consideration of invasive procedures such as nucleoplasty or laser discectomy.
- Conservative therapy (physical therapy, medications) is typical first-line care
- Epidural steroid injection is a commonly used nonoperative comparator prior to invasive interventions
Prior conservative therapy observed in studies
Prior conservative therapy was required or observed in key trials. For example, the Gerszten randomized trial enrolled patients who had prior epidural steroid injections without sustained relief; other trials compared nucleoplasty to conservative therapy or to epidural steroid injections.
- Gerszten RCT required prior epidural steroid injection (3 weeks–6 months)
- Trials compared nucleoplasty with conservative therapy or epidural steroid injections
Clinical Background
Discogenic low back pain refers to low back pain without radicular findings in the presence of radiologic degenerative disc disease. Minimally invasive percutaneous techniques such as laser discectomy (needle or catheter insertion into the disc nucleus with directed laser vaporization under fluoroscopic guidance) and disc nucleoplasty / radiofrequency coblation (use of bipolar radiofrequency energy to ablate nucleus material) are intended to reduce disc volume and relieve focal nerve compression. Typical management begins with conservative therapies (e.g., physical therapy, medications, epidural steroid injection), and these percutaneous procedures have been evaluated as alternatives to continued conservative care or to more invasive discectomy. The current evidence does not establish consistent long-term benefit for laser decompression, and randomized trial data for nucleoplasty are limited and have methodological constraints.
Procedure and Outcome Measure Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.